Basilea-Astellas' antifungal treatment gets orphan status from FDA

05/29/2013 | Pharmaceutical Business Review Online

The FDA granted orphan-drug designation to Basilea Pharmaceutica and Astellas Pharma's experimental antifungal isavuconazole as a treatment for invasive aspergillosis. The intravenous and oral-broad spectrum drug is in late-stage studies for severe invasive fungal infections.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ